Abbvie (ABBV 1.30%), the Abbott spinoff that made its New York Stock Exchange debut at the start of the year, recently announced that its chief scientific officer will retire in the coming months. A new CSO has not yet been revealed, but is this something that investors need to watch? Can this appointment offer clues as to AbbVie's future strategy, much as a recent shake-up at Merck (MRK 1.80%) did? Health-care analyst Max Macaluso discusses this story in the following video.